{"groups":[{"description":"Lenalidomide: Capsules, Oral, 25 mg, once daily, on Days 1-21 Repeat every 28 days until participants met criteria for discontinuation of study drug Dexamethasone (Oral): On weeks without Elotuzumab dosing: Tablets, Oral, 40mg Repeat every 28 days until participants met criteria for discontinuation of study drug On weeks with Elotuzumab dosing: Tablets, Oral, 28 mg Repeat every 28 days until participants met criteria for discontinuation of study drug Dexamethasone (IV): On weeks without Elotuzumab dosing: Not Applicable (N/A) On weeks with Elotuzumab dosing: Solution, Intravenous (IV), 8 mg, weekly Repeat every 28 days until participants met criteria for discontinuation of study drug Elotuzumab (BMS-901608; HuLuc63): Solution, IV, 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1\\&2); Days 1 and 15 (cycles 3 and beyond) Repeat every 28 days until participants met criteria for discontinuation of study drug","id":"FG000","title":"Lenalidomide + Dexamethasone + Elotuzumab"},{"description":"Lenalidomide: Capsules, Oral, 25 mg, once daily, on Days 1-21 Regimen repeated every 28 days until participants met criteria for discontinuation of study drug Dexamethasone: Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22 Regimen repeated every 28 days until participants met criteria for discontinuation of study drug","id":"FG001","title":"Lenalidomide + Dexamethasone"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Participant no longer meets study criteria"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"7"}],"type":"Participant withdrew consent"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Adverse event unrelated to study drug"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"321"},{"groupId":"FG001","numSubjects":"325"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"319"},{"groupId":"FG001","numSubjects":"316"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"9"}],"type":"NOT COMPLETED"}],"title":"Randomized Participants"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"185"},{"groupId":"FG001","numSubjects":"185"}],"type":"Disease progression"},{"reasons":[{"groupId":"FG000","numSubjects":"39"},{"groupId":"FG001","numSubjects":"45"}],"type":"Study drug toxicity"},{"reasons":[{"groupId":"FG000","numSubjects":"31"},{"groupId":"FG001","numSubjects":"37"}],"type":"Adverse event unrelated to study drug"},{"reasons":[{"groupId":"FG000","numSubjects":"28"},{"groupId":"FG001","numSubjects":"18"}],"type":"Participants request to discontinue study treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"4"}],"type":"Administrative reason by sponsor"},{"reasons":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"14"}],"type":"Other reasons"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"11"}],"type":"Participant withdrew consent"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Participant no longer meets study criteria"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Poor/non-compliance"}],"milestones":[{"achievements":[{"comment":"1 participant was randomized to treatment E-Ld but received treatment Ld","groupId":"FG000","numSubjects":"318"},{"comment":"1 participant was randomized to treatment E-Ld but received treatment Ld","groupId":"FG001","numSubjects":"317"}],"comment":"Participants treated","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"comment":"Participants still on treatment","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"318"},{"groupId":"FG001","numSubjects":"317"}],"type":"NOT COMPLETED"}],"title":"Treated Participants"}],"preAssignmentDetails":"646 participants were randomized and 635 were treated"}